Classical Hodgkin lymphoma · 10 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
BeEAM Variant #01 | — | R 18 312 | — | — | — | ~1 | ~R 18 312 indirect | — |
CBV-Mx Variant #01 Partial | — | R 16 619 | — | — | — | ~1 | ~R 16 619 indirect | — |
CBV Variant #01 Partial | — | R 9 597 | — | — | — | ~1 | ~R 9 597 PFS proxy · indirect | 2 |
FEAM Variant #01 Partial | — | R 5 029 | — | — | — | ~1 | ~R 5 029 indirect | — |
BEAM, then allo HSCT Variant #01 Partial | — | R 4 346 | — | — | — | ~1 | ~R 4 346 indirect | — |
BEAM Variant #01 Partial | — | R 4 346 | — | — | — | ~1 | ~R 4 346 indirect | — |
Fludarabine and Melphalan, then allo HSCT Variant #02 Partial | — | — | — | ~9.0 mo | — | ~1 | — | 2 |
Radiation therapy N/A - radiation | — | — | 49d | — | — | — | — | 1 |
Fludarabine, Melphalan, Alemtuzumab, then allo HSCT Partial | — | — | — | — | — | — | — | — |
Flu-Mel, then allo HSCT Partial | — | — | — | — | — | — | — | — |
10 of 10 regimens shown